GE Healthcare has announced the opening of a biotechnology manufacturing centre at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, in Stevenage, UK.
In the first half of 2019, the centre will start producing a fiber-based purification platform, which has the potential to significantly improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies and viral vectors.
The fiber-based purification platform comprises material with a unique proprietary structure. This has the potential to significantly improve process speed, flexibility and robustness during purification which is a key step in the manufacturing of biopharmaceuticals.
Olivier Loeillot, General Manager, BioProcess at GE Healthcare Life Sciences said, “This technology will bring real efficiency and productivity advantages for biopharmaceutical manufacturers as they move towards integrated, connected or continuous operations. The fiber-based chromatography technology developed and manufactured in Stevenage will extend GE Healthcare’s start-to-finish bioprocess purification portfolio.”
GE Healthcare is the $19 billion healthcare business of GE.
